Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$31.8 million.

  • Vanda Pharmaceuticals' Free Cash Flow fell 11562.2% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 35575.52%. This contributed to the annual value of -$16.2 million for FY2024, which is 23083.43% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Free Cash Flow stood at -$31.8 million, which was down 11562.2% from -$15.6 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Free Cash Flow registered a high of $31.8 million during Q1 2023, and its lowest value of -$33.6 million during Q1 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Free Cash Flow averaged around $537736.8, with its median value being $4.0 million (2022).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Free Cash Flow surged by 80804.69% in 2021, and later plummeted by 61080.04% in 2024.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Free Cash Flow stood at $26.5 million in 2021, then tumbled by 65.43% to $9.2 million in 2022, then crashed by 143.54% to -$4.0 million in 2023, then soared by 49.03% to -$2.0 million in 2024, then crashed by 1465.09% to -$31.8 million in 2025.
  • Its last three reported values are -$31.8 million in Q3 2025, -$15.6 million for Q2 2025, and -$33.6 million during Q1 2025.